Hertumab (Trastuzumab) Injection
Hertumab Injection is a targeted therapy monoclonal antibody used to treat cancers that overexpress the HER2 protein, primarily HER2-positive breast cancer (early-stage, advanced, or metastatic) and HER2-positive stomach/gastroesophageal junction cancer, working by blocking HER2 signals to stop cancer cell growth and trigger cell death, often combined with chemotherapy. Trastuzumab (Brand name Hertumab) is available in Delhi, India. Product Name Hertumab Salt Composition Trastuzumab Product Form / Net Quantity Injection 30mg/ml Marketed By Glenmark Availability In Stock at Aark Locations Prescription Required Buy 100% authentic medicines from Aark Pharmaceuticals. Top CFA & pharma distributor supplying hospitals, clinics & patients across India. * Get the best price & exclusive discounts o
About Hertumab (Trastuzumab) Injection
Description Is Trastuzumab Injection available in India? Yes, Trastuzumab Injection is available in India . It is marketed under the brand name Hertumab among others. It is used to treat HER2-overexpressing new or metastatic (cancer that has spread) breast cancer. It can be used alone or with other cancer medicines (eg, carboplatin, cyclophosphamide, docetaxel, doxorubicin, paclitaxel). The new indications are: HER2-Low Metastatic Breast Cancer: Trastuzumab deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-Low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Locally Advanced or Metastatic Gastric Cancer: Trastuzumab deruxtecan is now indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab based regimen. Trastuzumab deruxtecan was earlier approved by Drug Controller General of India (DCGI), for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. Approved in May 2023 for the treatment of metastatic breast cancer. In March 2024, the Central Drugs Standard Control Organisation (CDSCO) approved the drug for two additional indications: HER2-low metastatic breast cancer and HER2-positive gastric cancer. Who is the CFA, distributor, and retailer for Hertumab (Trastuzumab) Injection in India? Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for Hertumab (Trastuzumab) Injections in India. It is marketed by Glenmark . Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of Glenmark products, including advanced cancer treatments. The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup. How much do Hertumab Injection cost in Delhi, India? Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals Seller Name: Aark Pharmaceuticals Private Limited.
